Cure8 news brief
New Phase III data on guselkumab are directly relevant because they report long-term (3-year) maintenance results for Crohn’s disease and one-year fistula outcomes for people with perianal disease — areas that affect disease control, complications, and treatment choices.
Adults with moderately to severely active Crohn’s disease; people with Crohn’s and perianal fistulas; clinicians treating IBD; researchers and patients following biologic treatment options.
This news summarizes company-reported Phase III findings presented at UEG Week from the GALAXI and FUZION studies. The GALAXI programme data are described as showing continued benefit and a consistent safety profile through Week 144 of maintenance treatment.
The FUZION one-year results are reported as late-breaking and focus on fistula remission in perianal disease. The report comes from a pharmaceutical/industry news source summarizing conference presentations; the article text available on the site is behind a registration wall, and Cure8 has classified content based on the accessible text and metadata.
If you want details such as exact patient numbers, statistical outcomes, safety event rates, or subgroup analyses, look for the original conference abstracts, the company press release, or peer-reviewed publications for the full data.
Source is an industry news outlet summarizing conference presentations; full study details appear behind a registration wall. Conference presentations and company reports give early access to results but may precede peer-reviewed publication. Exact efficacy and safety data should be confirmed from the original abstracts, company releases, or journal articles.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Perianal fistulas are a common, debilitating complication of Crohn’s disease; longer-term data on treatments that can produce durable fistula remission are directly relevant to patients and clinicians managing this...
Perianal fistulas are a significant complication of Crohn’s disease that can be hard to treat. A phase 3 trial reported that guselkumab improved combined fistula remission versus placebo, which could represent a new...
Narrowing (stenosis) can cause obstructive symptoms and often leads to surgery; evidence that a biologic—guselkumab—may improve non-passable stenosis and reduce fibrosis-associated biology could affect treatment planning...
